Columbus Circle Capital Corp II (CMIIU)
Price:
9.97 USD
( - -0.01 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
CM Life Sciences II Inc. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the life sciences sector. The company was incorporated in 2020 and is based in New York, New York.
NEWS
Columbus Circle Capital Corp. II and Cohen & Company Inc. Announce Completion of $230,000,000 Initial Public Offering
globenewswire.com
2026-02-12 17:00:00New York, NY, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Columbus Circle Capital Corp. II (Nasdaq: CMIIU) (the “Company”) and Cohen & Company Inc. (NYSE American: COHN) (“Cohen & Company”) today announced the closing of the Company's initial public offering of 23,000,000 units, which included 3,000,000 units issued pursuant to the full exercise by the underwriters of their over-allotment option. The offering was priced at $10.00 per unit, resulting in gross proceeds of $230,000,000.
Columbus Circle Capital Corp II Announces Pricing of $200,000,000 Initial Public Offering
globenewswire.com
2026-02-10 18:32:00New York, NY, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Columbus Circle Capital Corp II (NASDAQ: CMIIU) (the “Company”) today announced the pricing of its initial public offering of 20,000,000 units at a price of $10.00 per unit. The Company's units are expected to be listed on the Nasdaq Global Market (“Nasdaq”) under the symbol “CMIIU” and will begin trading on February 11, 2026. Each unit consists of one Class A ordinary share of the Company and one-third of one redeemable warrant, with each whole warrant entitling the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, subject to certain adjustments. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “CMII” and “CMIIW,” respectively. The Company has granted the underwriters a 45-day option to purchase up to an additional 3,000,000 units at the initial public offering price to cover over-allotments, if any. The closing of the offering is anticipated to take place on or about February 12, 2026, subject to customary closing conditions.
U.S. IPO Weekly Recap: Equipment Rental Rises While Crypto Company Crashes In 2-IPO Week
seekingalpha.com
2026-01-23 22:45:00Two operating companies priced IPOs this week, along with six SPACs. Ten issuers submitted initial filings this week, with five operating companies and five SPACs. Four IPOs are currently scheduled in the week ahead, and some smaller issuers may join the calendar throughout the year.
SomaLogic and Twist Bioscience Corporation announce partnership to discover novel therapeutic targets and antibodies
globenewswire.com
2021-08-18 08:00:00BOULDER, Colo. & SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) -- CM Life Sciences II (Nasdaq: CMIIU) and SomaLogic, Inc., a leader in AI-data driven proteomics technology, and Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a collaboration aimed at creating novel antibodies and enabling innovative drug discovery based on key disease biomarkers. The collaboration will allow Twist to use the SomaScan® Platform to quickly identify antibodies against targets resulting from SomaLogic's industry-leading 7,000-plex assay, believed to be one of the broadest views of the proteome available.
ARK Investment Leans Into Biotech and Telecom Holdings
gurufocus.com
2021-07-12 15:39:21Catherine Wood (Trades, Portfolio)'s ARK Investment has revealed additions to three biotechnology and telecommunications holdings according to GuruFocus' Real-Time Picks, a Premium feature.
SomaLogic Customizable Protein Panels With Industry-Leading 7,000-Plex Assay Now Available
businesswire.com
2021-07-06 08:01:00NEW YORK & BOULDER, Colo.--(BUSINESS WIRE)--CM Life Sciences II (NASDAQ: CMIIU) and SomaLogic, Inc., a global leader in proteomics technology, announced today that their new customizable protein panel products are now available to pharma, biotechnology and academic research customers seeking the power of the company's proteomics menu of 7,000 proteins. “Our customers have expressed a strong desire to use our platform to focus their work on smaller numbers of proteins of interest for drug discov
SomaLogic Latest to Take SPAC Route to Public Markets
gurufocus.com
2021-04-02 14:48:08SomaLogic is joining the growing number of companies going public via special purpose acquisition companies. The Boulder, Colorado-based health care company plans to merge with CM Life Sciences II Inc. (NASDAQ:CMIIU), whose lead entity is Casdin Capital LLC, a life-sciences investment group with $1.3 billion in assets under management.
CM Life Sciences II Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Pricing of Upsized $240 Million Initial Public Offering
businesswire.com
2021-02-22 22:30:00NEW YORK--(BUSINESS WIRE)--CM Life Sciences II Inc. (the “Company”) announced today that it priced its initial public offering of 24,000,000 units at $10.00 per unit. The units will be listed on The Nasdaq Capital Market (“Nasdaq”) and trade under the ticker symbol “CMIIU” beginning February 23, 2021. Each unit consists of one share of Class A common stock and one-fifth of one redeemable warrant, with each whole warrant exercisable to purchase one share of Class A common stock at a price of $11
No data to display
No data to display
Columbus Circle Capital Corp. II and Cohen & Company Inc. Announce Completion of $230,000,000 Initial Public Offering
globenewswire.com
2026-02-12 17:00:00New York, NY, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Columbus Circle Capital Corp. II (Nasdaq: CMIIU) (the “Company”) and Cohen & Company Inc. (NYSE American: COHN) (“Cohen & Company”) today announced the closing of the Company's initial public offering of 23,000,000 units, which included 3,000,000 units issued pursuant to the full exercise by the underwriters of their over-allotment option. The offering was priced at $10.00 per unit, resulting in gross proceeds of $230,000,000.
Columbus Circle Capital Corp II Announces Pricing of $200,000,000 Initial Public Offering
globenewswire.com
2026-02-10 18:32:00New York, NY, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Columbus Circle Capital Corp II (NASDAQ: CMIIU) (the “Company”) today announced the pricing of its initial public offering of 20,000,000 units at a price of $10.00 per unit. The Company's units are expected to be listed on the Nasdaq Global Market (“Nasdaq”) under the symbol “CMIIU” and will begin trading on February 11, 2026. Each unit consists of one Class A ordinary share of the Company and one-third of one redeemable warrant, with each whole warrant entitling the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, subject to certain adjustments. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “CMII” and “CMIIW,” respectively. The Company has granted the underwriters a 45-day option to purchase up to an additional 3,000,000 units at the initial public offering price to cover over-allotments, if any. The closing of the offering is anticipated to take place on or about February 12, 2026, subject to customary closing conditions.
U.S. IPO Weekly Recap: Equipment Rental Rises While Crypto Company Crashes In 2-IPO Week
seekingalpha.com
2026-01-23 22:45:00Two operating companies priced IPOs this week, along with six SPACs. Ten issuers submitted initial filings this week, with five operating companies and five SPACs. Four IPOs are currently scheduled in the week ahead, and some smaller issuers may join the calendar throughout the year.
SomaLogic and Twist Bioscience Corporation announce partnership to discover novel therapeutic targets and antibodies
globenewswire.com
2021-08-18 08:00:00BOULDER, Colo. & SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) -- CM Life Sciences II (Nasdaq: CMIIU) and SomaLogic, Inc., a leader in AI-data driven proteomics technology, and Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a collaboration aimed at creating novel antibodies and enabling innovative drug discovery based on key disease biomarkers. The collaboration will allow Twist to use the SomaScan® Platform to quickly identify antibodies against targets resulting from SomaLogic's industry-leading 7,000-plex assay, believed to be one of the broadest views of the proteome available.
ARK Investment Leans Into Biotech and Telecom Holdings
gurufocus.com
2021-07-12 15:39:21Catherine Wood (Trades, Portfolio)'s ARK Investment has revealed additions to three biotechnology and telecommunications holdings according to GuruFocus' Real-Time Picks, a Premium feature.
SomaLogic Customizable Protein Panels With Industry-Leading 7,000-Plex Assay Now Available
businesswire.com
2021-07-06 08:01:00NEW YORK & BOULDER, Colo.--(BUSINESS WIRE)--CM Life Sciences II (NASDAQ: CMIIU) and SomaLogic, Inc., a global leader in proteomics technology, announced today that their new customizable protein panel products are now available to pharma, biotechnology and academic research customers seeking the power of the company's proteomics menu of 7,000 proteins. “Our customers have expressed a strong desire to use our platform to focus their work on smaller numbers of proteins of interest for drug discov
SomaLogic Latest to Take SPAC Route to Public Markets
gurufocus.com
2021-04-02 14:48:08SomaLogic is joining the growing number of companies going public via special purpose acquisition companies. The Boulder, Colorado-based health care company plans to merge with CM Life Sciences II Inc. (NASDAQ:CMIIU), whose lead entity is Casdin Capital LLC, a life-sciences investment group with $1.3 billion in assets under management.
CM Life Sciences II Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Pricing of Upsized $240 Million Initial Public Offering
businesswire.com
2021-02-22 22:30:00NEW YORK--(BUSINESS WIRE)--CM Life Sciences II Inc. (the “Company”) announced today that it priced its initial public offering of 24,000,000 units at $10.00 per unit. The units will be listed on The Nasdaq Capital Market (“Nasdaq”) and trade under the ticker symbol “CMIIU” beginning February 23, 2021. Each unit consists of one share of Class A common stock and one-fifth of one redeemable warrant, with each whole warrant exercisable to purchase one share of Class A common stock at a price of $11